A-Bio was founded on twenty billion won. However, it had grown tremendously in just one year. It was common for small or medium-sized pharmaceutical companies to become a little bit smaller than big pharma companies with just one powerful drug. But A-Bio had already commercialized well over a dozen drugs like that. They had stem cells and Cas9, base technologies that could change the trend of future medicine.0

As a subsidiary, A-Bio had the A-Bio Cancer Laboratory and the Next-Generation Hospital. A-Gen Life was a subsidiary of A-Gen, but it was only run by Yoon Dae-Sung; A-Bio and Young-Joon actually had the majority of the shares.0

There had never been a company that had undergone such a transformation in such a short period of time. As such, the evaluation of A-Bio’s worth varied from expert to expert. The situation was especially chaotic before the merger with A-Gen. Experts had one of three opinions:0

1. A-Bio had higher market capitalization than A-Gen.0

2. A-Bio wasn’t as big as A-Gen yet.0

3. A-Bio was similar to A-Gen.0

A-Gen was a huge pharmaceutical company that was valued at two hundred trillion won and competed with Schumatix, Roche, and Conson & Colson. A-Bio, which was only valued at twenty billion won, was competing for...0